Drug Search Results
More Filters [+]


Alternative Names: bay1238097, bay 1238097
Latest Update: 2016-03-09
Latest Update Note: Clinical Trial Update

Product Description

An inhibitor of the Bromodomain (BRD) and Extra-Terminal domain (BET) family of proteins, with potential antineoplastic activity. Upon administration, the BET inhibitor BAY1238097 binds to the acetylated lysine recognition motifs on the BRD of BET proteins, thereby preventing the interaction between BET proteins and histones. This disrupts chromatin remodeling and prevents the expression of certain growth-promoting genes. This leads to an inhibition of tumor cell growth. BET proteins (BRD2, BRD3, BRD4 and BRDT) are transcriptional regulators that bind to acetylated lysines on the tails of histones H3 and H4, and regulate chromatin structure and function; they play an important role in the modulation of gene expression during development and cellular growth. (Sourced from: https://www.cancer.gov/publications/dictionaries/cancer-drug/def/bet-inhibitor-bay1238097)

Mechanisms of Action: BET Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Elanco Animal Health
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for BAY1238097

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Lymphoma|NUT Carcinoma|Multiple Myeloma|Small Cell Lung Cancer|Non-Small-Cell Lung Cancer|Acute Myeloid Leukemia|Melanoma



Trial Status


Primary Completion Date

Probability of Success




Lymphoma|Melanoma|Non-Small-Cell Lung Cancer|Small Cell Lung Cancer|Acute Myeloid Leukemia|Multiple Myeloma|NUT Carcinoma


Recent News Events